Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom topic
No spam. Unsubscribe anytime.
Kratom ban bill advances after emotional family testimony and divided expert opinions
Summary
House Bill 1649 — which would ban kratom and related alkaloids — was advanced to finance, ways and means after testimony from the Davenport family, addiction clinicians, pharmacologists and patient‑advocates who sharply disagreed about whether regulation or prohibition is appropriate.
The Judiciary Committee advanced a bill that would ban kratom in Tennessee after a two‑hour hearing that featured emotional family testimony, addiction clinicians describing rising treatment demand, and scientists who recommended regulation rather than prohibition.
Sponsor (speaker 15) said House Bill 16‑49 would ban kratom in all forms, establish criminal penalties, expand toxicology testing, require medical examiners to test for kratom in suspected overdose deaths and direct the Department of Labor to add kratom to workplace drug definitions. "This bill addresses the growing public health and safety concerns," the sponsor said.
Karen Davenport (speaker 16) told the committee her 27‑year‑old son Matthew died two years earlier and that mitragynine — identified in postmortem testing — was part of a combination of substances found in his system. "Nothing this committee does today will bring my son, Matthew, back. But what you do here today may determine whether another Tennessee family has to experience the same loss," she said.
Scientists and clinicians sharply debated the underlying evidence and policy response. Dr. Jack Henningfield (speaker 12), a kratom researcher formerly with Johns Hopkins and NIDA, told lawmakers there is a scientific distinction between natural kratom leaf and concentrated or synthetic 7‑hydroxymitragynine and argued regulation targeted at 7‑hydroxy and product standards would reduce deaths without criminalizing users. "We need regulation, not prohibition," he said, and noted most overdose deaths involve other substances.
Physicians treating addiction and recovery (speakers 14 and 17) described clinics seeing a rising number of patients with kratom or kratom‑linked presentations and urged removal from commerce. Dr. Heidi Sikora (speaker 18) and Sheldon Bradshaw (speaker 19) warned that banning the plant could harm patients who rely on natural kratom for symptom control, and they urged narrow bans on problematic synthetic alkaloids instead.
After questions that focused on chemistry, toxicology, testing, and the practical effects of a ban, the committee voted to move House Bill 16‑49 to finance, ways and means; the clerk reported 16 ayes, 2 nos and 1 present not voting. The vote advances the measure for additional fiscal and policy review; committee members signaled they took no immediate action to criminalize users within the committee hearing itself.
